Literature DB >> 23277207

Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: differentiation between choroidal scars and active lesions.

Pascal B Knecht1, Alessandro Mantovani, Carl P Herbort.   

Abstract

When following Vogt-Koyanagi-Harada disease (VKH), indocyanine green angiography (ICGA) is crucial in the subacute and convalescent stages of the disease in order to detect subclinical choroiditis and prevent the development of 'sunset glow' fundus. Hypofluorescent dark dots (HDDs) indicate persisting granulomas in the choroid. However, probably as a result of the healing process of choroidal granulomas, stromal choroidal fibrosis can also be shown by HDDs. We present two cases where intravenous corticosteroid administration because of persistent HDDs led to resolution of lesions in one case while they persisted in the other case. We reviewed the medical history of two VKH patients. Complete routine work-up for patients with posterior uveitis was performed. The charts were screened for the presence of HDDs by ICGA in the subacute and convalescent stages of the disease before and after administration of body weight-adapted pulse intravenous methylprednisolone (PIM). The evolution of HDDs was studied and compared in both patients. A female patient presented with a persistent bilateral granulomatous panuveitis compatible with VKH. Cerebrospinal fluid analysis had shown lymphocytic pleocytosis. At presentation, therapy consisted of oral prednisone 80 mg/day. Prednisone was tapered down to 22 mg/day over 3 months, when a recurrence occurred with the presence of disseminated HDDs. PIM was administered, followed by oral corticosteroids. After 8 days of therapy, ICGA showed an almost complete disappearance of HDDs. A girl presented with bilateral panuveitis and widespread depigmented areas of her fundus. Cerebrospinal fluid analysis showed monocytic pleocytosis. Because of relative resistance to oral inflammation suppressive therapy (IST), PIM was administered for 3 days. Nevertheless, ICGA showed persistence of HDDs. Therapy was continued, and 3 months later, a follow-up ICGA still depicted numerous HDDs. Another PIM course was given, which had no effect on ICGA signs. HDDs in this case were interpreted as stromal choroidal scars. ICGA-guided therapy (mainly HDD evolution monitoring) helps to eradicate occult stromal disease in VKH and avoids 'sunset glow' fundus, by allowing precise adjustment of therapy. In some cases, HDDs do not represent active lesions but presumed intrastromal scars which need to be identified. A limited course of maximal IST including PIM can unmask such cases and avoid overtreatment of these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23277207     DOI: 10.1007/s10792-012-9692-4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  23 in total

1.  Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease.

Authors:  Chaokui Wang; Yuan Tian; Bo Lei; Xiang Xiao; Zi Ye; Fuzhen Li; Aize Kijlstra; Peizeng Yang
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-10       Impact factor: 4.799

2.  Optic disc swelling in Vogt-Koyanagi-Harada disease.

Authors:  Kumiko Nakao; Noriko Abematsu; Yuka Mizushima; Taiji Sakamoto
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-18       Impact factor: 4.799

3.  The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease.

Authors:  N Bouchenaki; C P Herbort
Journal:  Ophthalmology       Date:  2001-01       Impact factor: 12.079

4.  Indocyanine green angiography findings in initial acute pretreatment Vogt-Koyanagi-Harada disease in Japanese patients.

Authors:  Masaru Miyanaga; Tatsushi Kawaguchi; Kazunori Miyata; Shintaro Horie; Manabu Mochizuki; Carl P Herbort
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

5.  Increased IL-7 expression in Vogt-Koyanagi-Harada disease.

Authors:  Yan Yang; Xiang Xiao; Fuzhen Li; Liping Du; Aize Kijlstra; Peizeng Yang
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-27       Impact factor: 4.799

6.  The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.

Authors:  Ahmed M Abu El-Asrar; Suhail Hemachandran; Hani S Al-Mezaine; Dustan Kangave; Abdulrahman M Al-Muammar
Journal:  Acta Ophthalmol       Date:  2012-09-12       Impact factor: 3.761

7.  Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease.

Authors:  K Yamaki; K Gocho; K Hayakawa; I Kondo; S Sakuragi
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

8.  Quantitative evaluation of "sunset glow" fundus in Vogt-Koyanagi-Harada disease.

Authors:  S Suzuki
Journal:  Jpn J Ophthalmol       Date:  1999 Jul-Aug       Impact factor: 2.447

9.  Videofunduscopy and videoangiography using the scanning laser ophthalmoscope in Vogt-Koyanagi-Harada syndrome.

Authors:  A A Okada; T Mizusawa; J Sakai; M Usui
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

10.  Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease.

Authors:  Tatsushi Kawaguchi; Shintaro Horie; Nadia Bouchenaki; Kyoko Ohno-Matsui; Manabu Mochizuki; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2009-01-17       Impact factor: 2.031

View more
  11 in total

1.  Analysis of choroidal folds in acute Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography.

Authors:  Kotaro Tsuboi; Kei Nakai; Chiharu Iwahashi; Fumi Gomi; Yasushi Ikuno; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-10       Impact factor: 3.117

Review 2.  New concepts in the appraisal and management of birdshot retinochoroiditis, a global perspective.

Authors:  Marina Papadia; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2015-02-14       Impact factor: 2.031

3.  High prevalence of angle-closure glaucoma in Vogt-Koyanagi-Harada disease.

Authors:  Carlos Alvarez-Guzman; Jorge E Valdez-Garcia; Raul E Ruiz-Lozano; Alejandro Rodriguez-Garcia; Carlos F Navas-Villar; Curt Hartleben-Matkin; Miguel Pedroza-Seres
Journal:  Int Ophthalmol       Date:  2022-07-05       Impact factor: 2.031

4.  Early and sustained treatment modifies the phenotype of birdshot retinochoroiditis.

Authors:  Pascal B Knecht; Marina Papadia; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2013-10-01       Impact factor: 2.031

Review 5.  Vogt-Koyanagi-Harada syndrome - current perspectives.

Authors:  Abeir Baltmr; Sue Lightman; Oren Tomkins-Netzer
Journal:  Clin Ophthalmol       Date:  2016-11-24

6.  Brentuximab vedotin induced uveitis.

Authors:  Stijn Therssen; Stef Meers; Julie Jacob; Pieter-Paul Schauwvlieghe
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-18

7.  Choroidal bulging in patients with Vogt-Koyanagi-Harada disease in the non-acute uveitic stage.

Authors:  Viviane M Sakata; Felipe T da Silva; Carlos E Hirata; Walter Y Takahashi; Rogerio A Costa; Joyce H Yamamoto
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-02-18

Review 8.  Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.

Authors:  Marcelo Mendes Lavezzo; Viviane Mayumi Sakata; Celso Morita; Ever Ernesto Caso Rodriguez; Smairah Frutuoso Abdallah; Felipe T G da Silva; Carlos Eduardo Hirata; Joyce Hisae Yamamoto
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

9.  Near-infrared light and tumor microenvironment dual responsive size-switchable nanocapsules for multimodal tumor theranostics.

Authors:  Zhiyi Wang; Yanmin Ju; Zeeshan Ali; Hui Yin; Fugeng Sheng; Jian Lin; Baodui Wang; Yanglong Hou
Journal:  Nat Commun       Date:  2019-09-27       Impact factor: 14.919

Review 10.  Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease.

Authors:  Cristhian A Urzua; Carl Herbort; Rodrigo A Valenzuela; Ahmed M Abu El-Asrar; Lourdes Arellanes-Garcia; Ariel Schlaen; Joyce Yamamoto; Carlos Pavesio
Journal:  J Ophthalmic Inflamm Infect       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.